Page 12 - Mylan EpiPen

In September 2016, the New York State Attorney General

began an investigation into Mylan's EpiPen4Schools

program in New York to determine if the program's

contracts violated antitrust law and the West Virginia State

Attorney General opened an investigation into whether

Mylan had given the state the correct discount under the

Medicaid Drug Rebate Program and subpoenaed the

company when it refused to provide the documentation the
state requested. It questioned why EpiPen had been

classified as a generic rather a proprietary product in the
program since 1997; generic drugs have lower rebates (13%)

than proprietary drugs (23%), and price hikes for generic

drugs cannot be passed onto states.

September 2016, also saw a Silicon Valley engineering

consultancy (Wallace and Krevitt ) reverse engineer an

EpiPen and estimated the manufacturing and packaging

costs at about $8.02 a 90-plus-fold mark-up over the retail

price.